DDAVP Clamp in Medical Treatment

Mechanism and Pharmacology of DDAVP

Desmopressin (DDAVP) has direct effects on platelets that are not fully characterized, and it acts by increasing the concentration of von Willebrand factor and factor VIII 1

DDAVP is indicated for treatment of mild type I von Willebrand disease and mild hemophilia A with FVIII levels at least 5% of normal 2
DDAVP has been used to manage bleeding in patients on antiplatelet therapy, though evidence for efficacy is uncertain 1
Standard dosing for hemostatic purposes is 0.3 μg/kg diluted in 50 ml saline and infused over 30 minutes 3

Evidence suggests limited efficacy with newer antiplatelet agents like ticagrelor and prasugrel 1
DDAVP did not reduce bleeding in rabbits treated with prasugrel and did not correct platelet function in healthy volunteers treated with ticagrelor 1
Meta-analyses suggest DDAVP can reduce RBC transfusion, blood loss, and reoperations due to bleeding 1
However, the prophylactic use of DDAVP in cardiac surgery has shown no benefit in multiple meta-analyses 2
A randomized prospective trial in children undergoing cardiac surgery failed to identify a benefit for prophylactic DDAVP 2

DDAVP can cause systemic vasodilator effects leading to arterial hypotension, reactive tachycardia, and facial flushing 1
Rare cases of thromboembolic events have been reported, requiring caution in at-risk patients 1

For hemostatic purposes, DDAVP (0.3 μg/kg) is suggested for patients treated with platelet-inhibiting drugs or with von Willebrand disease (Grade 2C recommendation) 3
DDAVP is not recommended for routine use in bleeding trauma patients (Grade 2C recommendation) 3
For patients with type 2B VWD, human-derived medium-purity FVIII concentrates complexed to Willebrand factor are preferred over DDAVP 4
Platelet function testing may help identify patients who would benefit from DDAVP therapy 3